{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:14:35Z","timestamp":1777936475607,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"De Faire Medical AB"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Nutr Metab Insights"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>BeaT-2\/Sugarburner is a nutritional supplement based on a co-existing microbial consortium of bacterial strains. The purpose of this study was to investigate potential beneficial effects of the supplement versus placebo on glycemic control and on biomarkers of inflammation, insulin resistance and \u00df-cell dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 40 Patients with type 2 diabetes (31 male, 9 female, age:65.5\u2009\u00b1\u20098.0\u2009years, BMI: 33.6\u2009\u00b1\u20095.5\u2009kg\/m\n                      <jats:sup>\u00b2<\/jats:sup>\n                      , HbA1c: 7.2\u2009\u00b1\u20090.9%) were included into the study. They were randomized to receive 2 capsules of either BeaT-2 or placebo once daily for 6\u2009weeks. Observation parameters were time in normoglycemia as assessed by continuous glucose monitoring, and biomarkers of glycemic control, \u00df-cell function, insulin resistance and chronic systemic inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Time in range was stable with BeaT-2 between weeks 0 and 2 versus weeks 4 and 6, while it slightly impaired with placebo (\u22124%, n.s.). At endpoint, there were significant improvements versus baseline with BeaT-2, but not with placebo for biomarkers of glycemic control (BeaT-2 vs Placebo, HbA1c: \u22120.3% vs 0.1%, fasting glucose: \u221214% vs +8%, both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.05), insulin resistance (insulin: \u221217% vs +14%, HOMA-IR: \u221226% vs +21%, both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.05), \u00df-cell dysfunction (intact proinsulin: \u221240% vs \u22122%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.05) and chronic systemic inflammation (adiponectin: +8% vs \u22128%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.05, hsCRP: \u221231% vs +27%, n.s.). In addition, observed changes in the lipid profiles and other parameters of metabolic syndrome were more favorable with BeaT-2 than with placebo. There were no differences between the groups with respect to number and type of adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The results observed with BeaT-2 were comprehensively indicative for improvements in the cardiometabolic situation. BeaT-2 may be a valuable supplement to any existing treatment combination in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11786388251413658","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:36:22Z","timestamp":1771500982000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Probiotic Nutritional Supplement Improves Glycemic Control and Biomarkers of Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-0887","authenticated-orcid":false,"given":"Andreas","family":"Pf\u00fctzner","sequence":"first","affiliation":[{"name":"Pf\u00fctzner Science &amp; Health Institute, Mainz, Germany"},{"name":"University for Digital Technologies in Medicine and Dentistry, Wiltz, Luxembourg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-2997","authenticated-orcid":false,"given":"Pamela","family":"Canaviri-Paz","sequence":"additional","affiliation":[{"name":"de Faire Medical AB, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina R.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Pf\u00fctzner Science &amp; Health Institute, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Sachsenheimer","sequence":"additional","affiliation":[{"name":"Pf\u00fctzner Science &amp; Health Institute, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiva","family":"Kalasauske","sequence":"additional","affiliation":[{"name":"Pf\u00fctzner Science &amp; Health Institute, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Jantz","sequence":"additional","affiliation":[{"name":"Pf\u00fctzner Science &amp; Health Institute, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"de Faire","sequence":"additional","affiliation":[{"name":"de Faire Medical AB, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau5812"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1600266"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.05.008"},{"key":"e_1_3_2_5_2","first-page":"4742","article-title":"The role of diet on gut microbiota composition","volume":"20","author":"Bibb\u00f2 S","year":"2016","unstructured":"Bibb\u00f2 S, Ianiro G, Giorgio V, et al. The role of diet on gut microbiota composition. Eur Rev Med. Pharmacol Sci. 2016;20:4742-4749.","journal-title":"Eur Rev Med. Pharmacol Sci"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002533"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/535047a"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1079\/PNS2002207"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-017-1445-8"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2015-133285"},{"key":"e_1_3_2_11_2","first-page":"2749","article-title":"Type 2 diabetes mellitus associated with obesity (diabesity). The central role of gut microbiota and its translational applications","volume":"12","author":"Ortega MA","year":"2020","unstructured":"Ortega MA, Fraile-Mart\u00ednez O, Naya I, et al. Type 2 diabetes mellitus associated with obesity (diabesity). The central role of gut microbiota and its translational applications. Nutr. 2020;12:2749.","journal-title":"Nutr"},{"key":"e_1_3_2_12_2","first-page":"1523","article-title":"Relationship between Mediterranean dietary polyphenol intake and obesity","volume":"10","author":"Castro-Barquero S","year":"2018","unstructured":"Castro-Barquero S, Lamuela-Ravent\u00f3s RM, Dom\u00e9nech M, Estruch R. Relationship between Mediterranean dietary polyphenol intake and obesity. Nutr. 2018;10:1523.","journal-title":"Nutr"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114510003363"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2017.08.003"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2012.189"},{"key":"e_1_3_2_16_2","first-page":"170","article-title":"Probiotics for gastrointestinal conditions: a summary of the evidence","volume":"96","author":"Wilkins T","year":"2017","unstructured":"Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 2017;96:170-178.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.3.682"},{"key":"e_1_3_2_19_2","first-page":"567","article-title":"Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance","volume":"50","author":"Pf\u00fctzner A","year":"2004","unstructured":"Pf\u00fctzner A, Kann PH, Pf\u00fctzner AH, et al. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab. 2004;50:567-573.","journal-title":"Clin Lab"},{"key":"e_1_3_2_20_2","first-page":"489","article-title":"Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk","volume":"51","author":"Sch\u00f6ndorf T","year":"2005","unstructured":"Sch\u00f6ndorf T, Maiworm A, Emmison N, Forst T, Pf\u00fctzner A. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab. 2005;51:489-494.","journal-title":"Clin Lab"},{"key":"e_1_3_2_21_2","first-page":"299","article-title":"\u201cGlucose cosmetics\u201d vs. personalised diabetes treatment \u2013 functional phenotyping as basis for individual therapy of type 2 diabetes article in German diabetes Stoffw","volume":"32","author":"Pf\u00fctzner A.","year":"2023","unstructured":"Pf\u00fctzner A. \u201cGlucose cosmetics\u201d vs. personalised diabetes treatment \u2013 functional phenotyping as basis for individual therapy of type 2 diabetes article in German diabetes Stoffw. Herz. 2023;32:299-306.","journal-title":"Herz"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2006.8.28"},{"key":"e_1_3_2_23_2","author":"International Diabetes Federation","year":"2019","unstructured":"International Diabetes Federation. IDF diabetes atlas. 2019.","journal-title":"IDF diabetes atlas"},{"key":"e_1_3_2_24_2","unstructured":"International Diabetes Federation. IDF diabetes atlas. 2025. https:\/\/www.diabetesatlas.org"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-012-0341-0"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3283557cd5"},{"key":"e_1_3_2_27_2","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes Association. 9","year":"2021","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(l 1):S111-S124.","journal-title":"Diabetes Care"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11450"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009085"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2817"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12243"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2013.848793"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2013.03.007"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0227"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114513003656"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2006.9.328"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114510002874"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-014-3901-z"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuw039"},{"key":"e_1_3_2_41_2","first-page":"485","article-title":"A biomarker concept for assessment of insulin resistance, \u00df-Cell function and chronic systemic inflammation in type 2 diabetes mellitus","volume":"54","author":"Pf\u00fctzner A","year":"2008","unstructured":"Pf\u00fctzner A, Weber MM, Forst T. A biomarker concept for assessment of insulin resistance, \u00df-Cell function and chronic systemic inflammation in type 2 diabetes mellitus. Clin Lab. 2008;54:485-490.","journal-title":"Clin Lab"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199200443-00007"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(98)00070-9"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/11786388221108919"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/11786388221141174"}],"container-title":["Nutrition and Metabolic Insights"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11786388251413658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11786388251413658","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11786388251413658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:33:08Z","timestamp":1777692788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11786388251413658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":44,"alternative-id":["10.1177\/11786388251413658"],"URL":"https:\/\/doi.org\/10.1177\/11786388251413658","relation":{},"ISSN":["1178-6388","1178-6388"],"issn-type":[{"value":"1178-6388","type":"print"},{"value":"1178-6388","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"11786388251413658"}}